TITLE:

CREATION AND PRELIMINARY CHARACTERIZATION OF PREGNANE X RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR KNOCKOUT RATS

Authors:

Kevin P Forbes, Evguenia Kouranova, Daniel Tinker, Karen Janowski, Doug Cortner, Aaron McCoy and Xiaoxia Cui

Horizon Discovery Group Company, Saint Louis, MO 63146
RUNNING TITLE:

PXR\(^{-/-}\) and CAR\(^{-/-}\) knock-out rats

Author for correspondence
Name: Kevin P. Forbes
Address: 2033 Westport Center Dr., Saint Louis, MO 63146
Email: k.forbes@horizondiscovery.com
Phone: 314-400-6609

Text pages #: 25
Table #: 5 supplemental tables
Figures #: 5 main figures, 6 supplemental figures
References #: 43
Word count Abstract: 234
Word count Introduction: 745
Word count Results: 1390
Word count Discussion: 1432
Abstract:

The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of Phase I (Cytochrome P450s), Phase II metabolizing enzymes and transporter genes in response to stimulation from xenobiotics, including prescription drugs. PXR and CAR knockout and humanized mouse models have proven useful. However, the rat being bigger in size, is a preferred model system for studying drug metabolism and pharmacokinetics. Here, we report the creation and preliminary characterization of PXR and CAR knockout rats and PXR/CAR double knockout rats. Whereas the expression of phase I and II enzymes and transporter genes were not upregulated by nuclear receptor-specific agonists PCN and TCPOBOP in the knockout rats, confirming the disruption of respective nuclear receptor(s), our data demonstrate that PXR appears to suppress the basal expression levels of Cyp2b2, Cyp3a23/3a1, Cyp3a2, Cyp3a18 and Ugt2b1 genes, while CAR maintains Cyp2b2 and Ugt2b1 and suppresses Cyp3a9 basal expression levels. In wild type rats, agonist binding of the nuclear receptors relieves the suppression, and target genes are expressed at levels comparable to knockout rats, with or without drug treatment. Overall, our findings are in good agreement with data obtained from human primary hepatocytes, nuclear receptor knock-out cell lines and mouse knock-out models. We believe these models are a useful complement to their mouse counterparts for drug development and as importantly, for functional studies on metabolic pathways involving nuclear receptors.
Introduction:

Biological systems are under constant bombardment of endogenous and foreign chemicals (xenobiotics) and have evolved three types of detoxification mechanisms: modification by Phase I enzymes, conjugation by Phase II enzymes, and transport (Xu et al., 2005). A major family of Phase I enzymes are encoded by the cytochrome P450 genes that either deactivate chemicals for their eventual excretion, or convert them into biologically active forms, primarily in the liver and the intestine. These metabolites can be subjected to further breakdown by Phase II enzymes, such as transferases, for elimination. In the last phase, transporter genes contribute to the uptake or efflux of these chemicals and/or the subsequent metabolites (Dogra et al., 1998; Pavek and Dvorak, 2008).

The expression of all three phases of enzymes are believed to be regulated by transcription factors, called nuclear receptors, which bind specific chemicals (ligands). Upon ligand binding, the subset of nuclear receptors that normally reside in the cytoplasm translocate into the nucleus to modulate the transcription of genes encoding enzymes that metabolize the ligands. The pregnane X receptor (PXR, official gene name NR1I2 in human and Nr1i2 in rodents) and constitutive androstane receptor (CAR, official gene name NR1I3 in human and Nr1i3 in rodents) are two vitamin D receptor-like nuclear receptors that belong to the nuclear receptor subfamily 1 (type II). PXR and CAR both have the canonical structure of nuclear receptors, with an N-terminus DNA binding domain (DBD), followed by a hinge and ligand binding domain. At the C-terminus, there is an AF2 (activation function 2) domain that is critical to transcription activation. Each DBD contains two zinc fingers that are conserved across species and between PXR and CAR (Xia and Kemper, 2007; Lichti-Kaiser et al., 2009). Upon ligand binding, both PXR and CAR form a complex with the retinoid X receptor (RXR) at the ligand binding domain as a heterotetramer (PXR-RXR) or...
heterodimer (CAR-RXR) (Xu et al., 2004; Wallace et al., 2013). Conformation of the AF2 domain is also changed upon ligand binding and recruits transcriptional activators to turn on target genes. Unlike the AF2 domain of PXR, the AF2 domain of CAR, as its name indicates, once in the nucleus, is constantly active and can turn on transcription without direct ligand binding of CAR (Xu et al., 2004).

Both PXR and CAR are highly conserved receptors across species and in the P450 genes they activate (Mangelsdorf and Evans, 1995; Giguere, 1999; Dickins, 2004; Pelkonen et al., 2008). PXR has primarily been linked to CYP3A (Human CYP3A4; Mouse Cyp3a11) induction and CAR to CYP2B (Human CYP2B6; Mouse Cyp2b10) control. Several other receptors are involved in P450 regulation and there can be significant crosstalk between receptors in terms of their regulation of these genes (Maglich et al., 2002; Dickins, 2004; Wang et al., 2012). In addition, studies have also linked transcriptional regulation of Phase II metabolizing enzymes as well as transporter genes via PXR and CAR (Tolson and Wang, 2010; Aleksunes and Klaassen, 2012; Amacher, 2016).

PXR and CAR can be activated by a variety of species-specific compounds (Timsit and Negishi, 2007; Wang et al., 2012). For example, pregnenlone-16α-carbonitrile (PCN) is a potent ligand for rodent PXR but not for human PXR which has a higher preference for rifampicin (RIF) (Guzelian et al., 2007; Scheer et al., 2008; Slatter et al., 2009). The human CAR is strongly activated by 6-(4-chlorophenyl) imidazo-[2,1-b][1,3] thiazole-5-carbaldehyde O-(3,4-dichloro-benzyl) oxime (CITCO), but the rodent CAR receptor has a preference for 1,4-Bis-[2-(3,5-dichloropyridyloxy)] benzene, 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy) benzene (TCPOBOP) not CITCO (Scheer et al., 2008; Slatter et al., 2009). Another compound, phenobarbital (PB), for example, activated both
human and rodent PXR and CAR receptors, as evident by comparing PB treatment of wild-type, knock-out and humanized mouse models (Scheer et al., 2008).

For studies on drug metabolism and pharmacokinetics, compared to mice, the larger size of the rat offers greater blood volume for sampling and higher accuracy in drug dosing. The rat also more closely resembles humans physiologically and allows easier transition into other assays, such as carcinogenicity testing. However, the rat has been under used as a model system due to the historical difficulty of its genome manipulation until the recent availability of nuclease technologies (For review, see the special collection starting with Aitman et al., 2016)

Here, we generated PXR and CAR individual and double knockout rats and characterized the models primarily by observing the effects on Phase I and Phase II drug/xenobiotic metabolizing enzymes and transporter gene expression in the liver with and without drug stimulation.

Materials and Methods:

Zinc-Finger Nucleases (ZFNs). ZFNs to target rat PXR and CAR were obtained from Sigma-Aldrich CompoZR product line. Each ZFN was designed to target within exon 2. ZFN mRNA was in vitro transcribed and validated as described previously (Cui et al., 2011).

Animal husbandry and microinjection. Rat work in this study was performed at SAGE Labs, now part of Horizon Discovery Group Company, which operated under approved animal protocols overseen by SAGE’s Institutional Animal Care and Use Committee (IACUC).

Sprague Dawley rats purchased from Charles River Laboratory (USA) were housed in standard cages and maintained on a 12 h light/dark cycle with ad libitum access to food and water. Four to five weeks old donors were injected with 20 units of PMS (pregnant mare serum) followed by 50 units of hCG (human chorionic gonadotropin) injection after 48 h and again before mating.
Fertilized eggs were harvested a day later for injection. ZFN mRNA was injected into the pronucleus of fertilized eggs. The final concentration of ZFN mRNA was 10 ng/µL. Recipient female rats were injected with 40 µg of LH-Rh 72 h before mating. Microinjected eggs were transferred to these pseudo-pregnant Sprague Dawley recipients.

**Founder Identification and breeding:** Live births from microinjections were sampled by toe clipping between 7-21 days after birth. Genomic DNA was purified, screened by PCR with oligonucleotide primers designed to flank the ZFN target site and the PCR products sequenced to verify mutations generated by ZFNS. Methods were described previously (Brown et al., 2013). The following oligonucleotide primers were used for PCR reactions and sequencing: PXR: 5'-TCTTGGAGAGCTATCAACG-3' and 5'-TCCCTTACATCCTCACAGGTC-3'; CAR: 5'-ACTCCTCCCACATCCAGGAGA-3' and 5'-GTCTCCACACACCACACAGT-3'. DNA sequencing of PCR products was performed by Elim Biopharma, Inc. (Hayward, CA USA). Founders with desired mutations were bred back to wild-type animals and then intercrossed for breeding to homozygosity and establishing colonies.

**Reagents.** A mouse monoclonal antibody was generated against a recombinant N-terminal rat PXR protein (Peptide sequence in Supplemental Figure 4) by ProMab Biotechnologies (Richmond, CA USA). PCN and TCPOBOP were obtained from Sigma-Aldrich (St. Louis, MO USA). The chemical structure for PCN found within Kliewer et al (1998) and Kelley et al (1985) for TCPOBOP.

**Drug response test.** Eight week old male wild-type, PXR<sup>-/-</sup>, CAR<sup>-/-</sup> and PXR<sup>-/-</sup>/CAR<sup>-/-</sup> rats were treated either with 2.5 mL/kg of corn oil (vehicle), PCN in corn oil (40 mg/mL; Dose equals 100 mg/kg) or TCPOBOP in corn oil (5 mg/mL; Dose equals 12.5 mg/kg) via intraperitoneal (I.P.) injection. PCN and TCPOBOP treatment ranges vary in the literature, the ranges are 20-100 mg/kg.
and 1-30 mg/kg respectively. Sixteen hours after injection, rats were euthanized and liver tissues were collected for RNA purification: WT vehicle (n=9), WT PCN and TCPOBOP (n=6); PXR\(^{-/-}\) and CAR\(^{-/-}\) vehicle, PCN and TCPOBOP (n=3). PXR\(^{-/-}\)/CAR\(^{-/-}\) vehicle (n=6), PCN and TCPOBOP (n=3).

\textbf{qRT-PCR}. Liver samples were homogenized in TRIzol Reagent (Life Technologies, USA) with ceramic beads using a Precellys homogenizer (PeqLab, Germany). Total RNA was isolated from homogenate and 100 µg of total RNA was DNase-I treated and purified (RNA Clean-up) using an RNeasy Mini-kit (Qiagen, USA). First strand cDNA was synthesized from 1µg of purified RNA using the RT\(^2\) First Strand Kit from RT\(^2\) Profiler PCR Array System (Qiagen). First strand cDNA was used in a customized RT\(^2\) Profiler\(\text{TM}\) PCR Array (Gene list in Supplemental Table 1). All quantitative PCR reactions were performed following the manufacturer’s recommended conditions on Bio-Rad’s CFX96 Real-Time PCR Detection System. For data analysis of the RT\(^2\) Profiler\(\text{TM}\) PCR Array, the Ct cutoff was set at 35 (limit of detection) and the average \(\Delta Ct\) was calculated with normalizing to five reference genes (Rplp1, Hprt1, Rpl13a, Ldha, ActB) for each biological replicate.

Taqman assays (Supplemental Table 2; ThermoFisher, USA) for Phase II enzymes and transporters were performed as single-plex reactions following the manufacturer’s recommended conditions on Bio-Rad’s CFX96 Real-Time PCR Detection System. Biological cDNAs were pooled and assayed in triplicate. Average fold-change was calculated normalizing to three reference genes (ActB, Hprt1 and Gapdh).

For rat PXR and CAR cDNAs, synthesis was performed as above with replacing the kit’s random primers with Oligo(dT)\(_{20}\) Primer (ThermoFisher, USA), followed by PCR amplification with the following specific oligonucleotides PXR 5’-ATGAGACCTGAGGAGGAGG-3’ and 5’-
TCAGCCGTCGCTGCTGCT-3'; CAR 5'-ATGACAGCTACTCTAACA-3' and 5'-
CCGACTTTGGAGTCTTGACTG-3'. PCR amplified cDNAs were resolved by 2% agarose E-
Gels (ThermoFisher, USA) for verification of full-length cDNA synthesis and then TA-cloned into
pCR4-TOPO (ThermoFisher, USA). DNA sequencing of cloned cDNAs was performed using T7
and T3 primers by Elim Biopharma, Inc. (Hayward, CA USA). Sequence results aligned together
using ContigExpress within Vector NTI Advance (Version 11.5.2; ThermoFisher, USA).

**Western Blot.** Briefly, 100 mg of liver tissue from wild-type and PXR<sup>±</sup> male rats was Dounce
homogenized in RIPA buffer plus protease inhibitors. After incubating on ice, the extract was
centrifuged to remove debris. The resulting supernatant was resolved by gradient protein gels,
transferred to nitrocellulose and then probed with the anti-PXR antibody at 1:500 at room
temperature for 1 hour. Secondary anti-mouse heavy plus light chain (Jackson Immuno Research
Labsoratories, West Grove, PA USA) was used at 1:50,000, room temperature for 1 hour. The blot
was developed with Super Signal West Pico (ThermoFisher, USA).

**Results:**

**Generation of PXR and CAR Knockout Rats.**

The rat PXR and CAR genes both contain 9 coding exons. Active ZFNs were validated to target
exon 2, the first coding exon of both genes coincidently (Figure 1). mRNAs of each pair of ZFNs
were combined at 1:1 ratio and microinjected into the pronucleus of fertilized eggs of Sprague
Dawley rats, which were then implanted into pseudopregnant females. One of ten live births from
PXR ZFN injections carried a 20 base pair (bp) deletion and was bred to establish a homozygous
colony. Four of twelve CAR rats had modified alleles, three of which were determined by
sequencing to have either a 10 bp or a 12 bp deletion. A male founder with a 10 bp deletion was
used to establish a homozygous colony. A simple PCR at the target site is used as a convenient genotyping screen to differentiate between wild type (WT), heterozygotes and homozygotes alleles (Supplemental Figure 1). Both deletions in PXR and CAR (Supplemental Figure 2A), led to a frameshift in the coding sequence that resulted in pre-mature termination of protein translation in the DNA binding domain (Supplemental Figure 2B). Animals homozygous for the respective deletions are referred to as PXR⁻/⁻ and CAR⁻/⁻ rats, and their crossbreeds, PXR⁻/⁻/CAR⁻/⁻ rats.

**Confirmation of PXR and CAR gene disruption.**

To find out whether the frameshift deletions in PXR⁻/⁻ and CAR⁻/⁻ rats led to mRNA degradation via the nonsense mediated decay pathway, we performed quantitative RT-PCR on RNA extracted from liver tissue. Comparable levels of PXR and CAR mRNAs were detected in their respective knockout models as compared to WT rats (data not shown). The deletions did not result in PXR or CAR mRNA degradation via nonsense mediated decay pathway. However, we were able to demonstrate that both mRNAs contain deletions that lead to out-of-frame translation of the messages and nonfunctional proteins (Supplemental Figure 3; Sequence verification of cloned cDNAs amplified with PXR or CAR specific oligonucleotides from WT, PXR⁻/⁻ and CAR⁻/⁻ liver RNA).

We then performed Western Blots using a monoclonal antibody raised specifically against the N-terminus of the rat PXR protein (Supplemental Figure 4A-B) on liver protein extracts. Here, we demonstrated that the major PXR peptide was detected in WT rats but absent in PXR⁻/⁻ samples (Figure 1C), indicating PXR gene disruption by the ZFN-introduced frame-shift. We were unable to find a suitable specific antibody to detect the rat CAR protein in liver extracts.
Impact on body weight by disruption of the nuclear receptors. Male and female WT, PXR⁻/⁻, CAR⁻/⁻ and PXR⁻/⁻/CAR⁻/⁻ rats were weighed weekly between the ages of three to fifteen weeks. Over the twelve-week period, male CAR⁻/⁻ and PXR⁻/⁻/CAR⁻/⁻ rats were both significantly lighter than wild-type rats (t-test; p-value <0.02). However, male PXR⁻/⁻ rats were heavier than the wild type rats, although not statistically significant (Figure 2A). Female PXR⁻/⁻ rats were heavier and CAR⁻/⁻ rats lighter than wild-type rats (t-test; p-value <0.02; Figure 2B) and PXR⁻/⁻/CAR⁻/⁻ rats were indistinguishable from wild type rats (Figure 2B). However, we have to point out that these wild type and knockout rats were not measured within the same time period or same season of the year, which may cause some variability. We superimposed our weight curves onto the wild type rat weight curves available from the vendor webpage, and all the weights fell within the range of 2 standard deviations from the mean (Supplemental Figure 5). We need to be cautious with our conclusions on relative weight change, but believe the general trend is reliable.

Regulation of hepatic Cytochrome P450 genes (Phase I enzymes) in WT, PXR⁻/⁻ and CAR⁻/⁻ male rats

We treated male wild-type (WT), PXR⁻/⁻, CAR⁻/⁻ and PXR⁻/⁻/CAR⁻/⁻ rats with corn oil (vehicle), PCN (PXR agonist) or TCPOBOP (CAR agonist) in corn oil, collected livers and analyzed gene expression on a custom quantitative RT-PCR array. The array included cytochrome P450 genes, drug transporters, nuclear receptors and controls (Supplemental Table 1). For easier comparison, the relative expression level of each gene is normalized to that of vehicle-treated wild type rats so that both basal expression level changes and drug treatment-mediated expression regulation can be captured in the same graph.

The prototypical cytochrome P450 genes regulated by PXR and CAR, Cyp2b and the Cyp3a subfamily members were analyzed in Figure 3 and Supplemental Table 3. Vehicle-treated samples
are shown in the left clusters of each panel in Figure 3. Cyp2b2 expression was more than 7-fold higher than that of WT in both PXR<sup>−/−</sup> and PXR<sup>−/−</sup>/CAR<sup>−/−</sup> rats, whereas in CAR<sup>−/−</sup> rats, Cyp2b2 mRNA was reduced to about 1/10<sup>th</sup> of the WT level (Figure 3A). Cyp3a1/3a23, Cyp3a18 and Cyp3a2 expression was also elevated significantly in PXR<sup>−/−</sup> and PXR<sup>−/−</sup>/CAR<sup>−/−</sup> rats when compared to WT rats (Figure 3B-D;). However, these genes were not affected by CAR disruption alone (CAR<sup>−/−</sup>, Fig. 3B-D). On the other hand, expression levels of another Cyp3a family member, Cyp3a9, was increased compared to WT levels in CAR<sup>−/−</sup> and PXR<sup>−/−</sup>/CAR<sup>−/−</sup> rats but not affected in PXR<sup>−/−</sup> (Figure 3E). Supplemental Table 3 is a detailed statistical analysis of basal expression levels for these five genes. In the meantime, no significant change in the basal expression level of the other genes within the array, including Cyp1a2, Abcb1a (Mdr1a), Abcb4 (Mdr2), Abcc1 (Mrp1), Abcc2 (Mrp2) and Abcc3 (Mrp3) as an example, was observed (Left cluster; Supplemental Figure 6).

The chemical activation of the rat Cyp2b2 and Cyp3a subfamily members Cyp3a23/3a1, Cyp3a18, Cyp3a2 upon the administration of PCN over vehicle treatment was observed in WT rats and CAR<sup>−/−</sup> rats, as expected for a PXR agonist (Middle clusters in Figure 3A-E; Table 1). The increased induction of Cyp2b2 by PCN observed in the CAR<sup>−/−</sup> rats compared to WT rats reflects the activation by PXR upon PCN treatment which compensates for the reduced CAR-dependent basal expression (Figure 3A). Interestingly, Cyp3a9 expression was activated by PCN in WT and PXR<sup>−/−</sup> and with no significant change in CAR<sup>−/−</sup> rats (Middle clusters in Figure 3E; Table 1). At the same time, expression levels of Cyp1a2, Abcb1a, Abcb4, Abcc1, Abcc2 and Abcc3 (other genes within the array; data not shown), were unchanged upon PCN treatment in all models (Middle cluster; Supplemental Figure 6).
Treatment with the known CAR agonist TCPOBOP activated Cyp2b2 in WT and PXR\(^{-/-}\) rats only, confirming its specificity for a functional CAR gene. Cyp3a23/3a1, Cyp3a18, Cyp3a2 and Cyp3a9 (right clusters in Figure 3 A-E and Table 2), along with Cyp1a2, Abcb1a, Abcb4, Abcc1, Abcc2 and Abcc3 (other genes within the array; data not shown), were not affected by TCPOBOP treatment in any of the models (Right cluster; Supplemental Figure 6).

**Regulation of hepatic transporters and Phase II enzymes in WT, PXR\(^{-/-}\) and CAR\(^{-/-}\) male rats**

Solute carrier (Slc) transporters Slc1a1 (Oatp1), Slc1a2 (Oatp2) Slc47a1 (Mate1) and Slc10a1 (Ntcp) were not assayed on the array. We screened RNAs from WT, PXR\(^{-/-}\), CAR\(^{-/-}\) and PXR\(^{-/-}\)/CAR\(^{-/-}\) rats for changes in basal and activated (PCN and TCPOBOP treatment) expression levels for these transporters separately (Figure 4; statistical analysis Supplemental Table 3 and Table 1 and 2; Taqman assays, Supplemental Table 2). Oatp2 was activated 3- to 4-fold by PCN treatment in WT and CAR\(^{-/-}\) rats and unchanged in PXR\(^{-/-}\) and PXR\(^{-/-}\)/CAR\(^{-/-}\) (Middle cluster; Figure 4A). There were no observed changes to Oatp1 and Ntcp transporter mRNA levels (Figure 4 B, C) and Mate1 was undetected in our assay (data not shown). In addition, no significant changes were observed in basal expression level or by TCPOBOP treatment in WT or any of the KO models (Left and Right clusters, Figure 4A-C, Table 2).

Phase II enzymes UDP-glucuronosyltransferase (Ugt1a6, Ugt2b1 and Ugt2b7), sulfotransferase (Sult2a2), Glutathione transferase (Gstm4) and Ephx1 basal and activated mRNA levels were determined using the same methods. Basal expression levels of Ugt2b1 was trending down 2-fold in CAR\(^{-/-}\) and upregulated ~4-fold in PXR\(^{-/-}\) and PXR\(^{-/-}\)/CAR\(^{-/-}\) rats and no observed changes in Ugt1a6 when compared to WT (Left clusters; Figure 5A and B; Supplemental Table 3). No significant changes were observed during PCN or TCPOBOP activation (Middle and right clusters; Figure 5A and B) and Ugt2b7 was undetected in our assay (data not shown). Sult2a2 was activated
~5- to 6-fold by PCN treatment in WT and CAR−/− rats and unchanged in PXR−/− and PXR−/−/CAR−/− (Middle cluster; Figure 5C and Table 1). Ephx1 was slightly induced by TCPOBOP in PXR−/− and PXR−/−/CAR−/− (Right cluster, Figure 5D) and we observed no changes in Gstm4 mRNA levels (Figure 5E).

**Discussion:**

In this study, we generated and characterized new knockout rat models for the nuclear receptors PXR and CAR. We observed changes in body weight, basal gene expression levels and loss of receptor mediated activation via exogenous ligands within these knockout lines.

Body weight change in the knockout models confirms the involvement of the nuclear receptors in metabolic pathways other than xenobiotic detoxification. In both genders, disruption of PXR led to weight gain, although in male rats the increase was not statistically significant. In addition, the male double KO rats were significantly lighter than wild type, whereas female double KO rats were comparable to wild type counterparts. The overall trend in rats is that disruption of PXR and CAR had an opposite effect on weight. This suggests that these nuclear receptors function on regulating basal expression levels of opposing sets of genes contributing to body mass. Their effect canceled each other out in the female rats. Similar observations on gender differences were made in mice (Uppal *et al.*, 2005; Anakk *et al.*, 2007), raising the question of whether it is sufficient to only use males for pharmacological tests as the standard method currently. Regardless, weight change is the first indication that the function of these genes were in fact altered in the knockout animals.

As expected, we observed upregulation of Cyp2b2, Cyp3a23/3a1, 3a18, 3a2, 3a9, Slco1a2 (Oatp2) and Sult2a2 genes by PCN compared to by vehicle in WT rats, but not in PXR−/− (Cyp3a9 the
exception; see below about CAR dependent PCN activation) and PXR+/CAR−/− rats, and upregulation of Cyp2b2 by TCPOBOP in WT and PXR−/− rats, but not in CAR−/− and PXR+/CAR−/− rats. It is well documented that PCN and TCPOBOP activation of these P450 genes is PXR and CAR-dependent in rodents respectively. The induction of the Oatp2 transporter by PCN has previously been reported in mice (Staudinger et al., 2003; Slatter et al., 2009) and rats (Guo et al., 2002; Slatter et al., 2009) and sulfotransferase (Sult) gene activation in primary rat and human hepatocytes (Fang et al., 2005) and mice (Aleksunes and Klaassen, 2012; Cui and Klaassen, 2016) is PXR dependent. This confirms that hepatic regulation of these genes in rats by PCN is PXR-dependent. We also observed a slight induction of Ephx1 under TCPOBOP activation in PXR−/− (Right cluster, Figure 5D) when compared to WT vehicle treated rats. However, this was not significant when comparing to vehicle treated PXR−/− rats, more than likely due to the slight increase in endogenous Ephx1 levels in these models.

Basal gene expression levels of Cyp2b2, Cyp3a23/3a1, 3a18, 3a2, and Ugt2b1 were increased in PXR−/− rats. Xie et al (2000) first reported on a PXR-null mouse and observed no changes in Cyp3a11 expression levels. However, subsequent studies around PXR in both mice and humans reported changes in genes closely related to the rat counterparts assessed in the current study. In PXR-null mice, Cyp3a11, Oatp2 and Mrp3 had higher basal mRNA levels in the liver than in wild type mice (Staudinger et al., 2001; Staudinger et al., 2003). In humans, allelic variants of PXR genes found in Caucasians and African Americans exhibit altered basal and/or induced transactivation of the CYP3A4 gene (Hustert et al., 2001; Zhang et al., 2001). Compared to PXR−/−, in CAR−/− rats, endogenous levels of Cyp3a9 was increased and Cyp2b2 and Ugt2b1 were decreased. In HepaRG cells, an in vitro proliferation-competent human hepatocyte line that closely resembles primary hepatocytes, the disruption of CAR led to changes in basal transcription levels
of several drug metabolizing and transporter genes (Li et al., 2016). In CAR knockout mice, Cyp2b13 (the mouse equivalent of rat Cyp2b21) expression was upregulated, whereas Cyp2b10 (the mouse equivalent of rat Cyp2b2) expression was down-regulated (Hernadez et al., 2010). In addition to changes in P450 levels, some Phase II enzymes and transporter mRNA expression levels were altered gender dependently in the liver and small intestine of PXR and CAR knock-out mice (Cheng and Klaassen, 2006; Aleksunes and Klaassen, 2012). These reported changes in endogenous gene expression levels is comparable to our observations in PXR−/− and CAR−/− rats. Changes caused by PXR or CAR disruption in basal gene expression levels can confound data analysis when only the ratio of vehicle versus treated samples is looked at.

The disruption of PXR greatly increased the expression levels of Cyp2b2 and Ugt2b1, suggesting that PXR suppresses them directly or indirectly in the absence of exogenous ligand, whereas CAR counterbalances PXR in maintaining their endogenous expression, demonstrated by the diminished Cyp2b2 and Ugt2b1 expression in CAR−/− rats (Figures 3A and 5A; Supplemental Table 3). Similarly, Luiser et al (2014) reported the same phenomenon for Cyp2b10 in PXR and CAR double knock-out mice. Unlike our data, the Ugt2b1 gene is down-regulated only in female TCPOBOP treated CAR-null mice and there is no change at the endogenous level or under PCN treatment in males or females (Aleksunes and Klaassen, 2012). Our observation on the regulation of Ugt2b1 at the endogenous level by both receptors in male rats may be species specific.

The major CYP3A metabolizing enzyme and PXR responsive gene in humans is CYP3A4, Cyp3a11 in mice and Cyp3a23/3a1 in rats. The rat Cyp3a9 is conserved across the other CYP3A “minor” subfamily members in mice (82% identity to Cyp3a13; 65% to Cyp3a11; tblastn, data not shown) and humans (76% to CYP3A7; 75% to CYP3A5; 69% to CYP3A43; 65% to CYP3A4; tblastn, data not shown). Mouse Cyp3a13 is induced by PCN and TCPOBOP (Slatter et al., 2009),
TCPOBOP (Cui and Klaassen, 2016), and the human CYP3A7 and CYP3A43 by RIF (PXR activator) not CITCO (CAR activator) (Kandel et al., 2016). In our study, we observed PCN activation of Cyp3a9 in WT and PXR<sup>-/-</sup> but not in CAR<sup>-/-</sup> and PXR<sup>-/-</sup>/CAR<sup>-/-</sup>. The endogenous levels of Cyp3a9 is significantly elevated in CAR<sup>-/-</sup> and PXR<sup>-/-</sup>/CAR<sup>-/-</sup> and slightly reduced in PXR<sup>-/-</sup> (not statistically significant) which suggests that CAR suppresses endogenous Cyp3a9 levels in the absence of exogenous ligand. Therefore, CAR regulates Cyp3a9 at the endogenous level and in this case, PCN induced expression, even in PXR KO rats. It is likely some other factors (other nuclear receptors per se) that bind PCN may also regulate Cyp3a9. The expression of the human CYP3A7 and CYP3A5 is elevated in CAR knock-out HepaRG cells when compared to WT with no change to CYP3A43 levels (Li et al., 2016). This suggests that some of the minor CYP3A family members are more CAR dependent than PXR, which regulates the major CYP3A family member across several species.

In summary, as expected, no nuclear receptor-specific agonist-mediated induction of Phase I and Phase II drug/xenobiotic metabolizing enzymes and transporter genes were observed in these knockout rats. Our results also suggest that PXR and CAR are involved in regulation of the basal expression level of different yet overlapping sets of drug metabolizing genes. When both PXR and CAR regulate a given gene, their effects are often counteractive, indicative of crosstalk between the two nuclear receptors. The regulation and signaling crosstalk between PXR and CAR has been linked to several other genes via protein-protein interactions (for review see Oladimeji et al., 2016; Pavek, 2016). This suggests we should look beyond PXR and CARs xenobiotic function and broaden our search for genes involved in other pathways that may be potentially disrupted by the loss of these protein-protein interactions.
Isogenic knockout models provide the perfect tool to dissect functions of individual genes, and these models are also useful in determining drug efficacy with or without nuclear receptors and whether inhibiting NRs would increase efficacy. PXR and CAR are both also drug targets themselves (Cheng et al., 2012; Gao and Xie, 2012; Banerjee et al., 2014). A full understanding of all the pathways the nuclear receptors are involved in would be critical for therapeutic success. Whereas our data only looked at a small portion of pathways PXR and CAR regulate: primarily Phase I and Phase II drug/xenobiotic metabolizing enzymes and transporter expression levels, many other targets may be regulated completely differently. Whole genome RNA profiling in different tissues of wild type and knockout animals would be highly informative on all pathways PXR and CAR are involved in and allow one to better predict metabolism of new drugs as well as potentially target PXR and CAR for therapeutics.

In the meantime, our data showed good correlation between the rat and human responses upon nuclear receptor disruption. These models complement the current mouse models. However, the rat has the advantage of size, and therefore ease of use and precision of measurements. Further studies will be needed to determine the advantage of these rat models over their mouse counterpart.
Acknowledgements:

We would like to thank Dr. Joe Warren and Yumei Wu for micro-injection, Lara Reid, Andre Chambers, Lauren Klaskala and Diana Ji for genotyping and Leanne Mushinski for colony management.

Authorship Contributions:

Participated in research design: Forbes, Kouranova, Cui.

Conducted experiments: Forbes, Kouranova, Tinker, Janowski, Cortner, McCoy.

Performed data analysis: Forbes, Cui.

Wrote or contributed to the writing of the manuscript: Forbes, Cui.
References:


Footnotes:

Competing interests statement:

All of the authors are full-time employees of Horizon Discovery, a CRO that sells the rat models described in the paper as well as provides drug testing services using these models.
Figure Legends:

**Figure 1. Deletion map for PXR and CAR Genes Generated via ZFNs.** The rat PXR (A) and CAR (B) transcripts each contain 9 exons. Black boxes with numbers represent exons and dashes introns. A double hash mark represents exons not shown (Exons 4 to 8 for both genes). Top sequence is the ZFN target sequence and bottom sequence with dashes represent mutant allele. (C) Wild-type (WT) and PXR⁻/⁻ liver protein extracts were analyzed for PXR expression by immunoblotting. Actin was used as an internal control. The size of the 50kD protein marker is listed on the left and the corresponding PXR and Actin band on the right of the gel with a solid dash mark.

**Figure 2. Weight curves.** Male (A) and female (B) wild-type (WT), PXR⁻/⁻, CAR⁻/⁻, and PXR⁻/⁻/CAR⁻/⁻ null animals were weighed (in grams) weekly starting at 3 weeks of age up to 15 weeks. The legend represents the plot order, from top to bottom, for simplicity. The order in A and B is PXR⁻/⁻, WT, PXR⁻/⁻/CAR⁻/⁻- and CAR⁻/⁻. Error bars represent calculated standard deviation.

**Figure 3. Fold Change in P450 Gene Expression Levels in Untreated and Treated WT and Knock-out Rats.** Vehicle (left cluster), PCN (middle cluster) and TCPOBOP (right cluster) treated rats Cyp2b2 (A), 3a23/3a1 (B), 3a18 (C), 3a2 (D) and 3a9 (E) expression levels were normalized to WT vehicle treated rats to calculate fold changes. Fold change calculated by dividing each $2^{-\Delta CT}$ replicate (biologic) by the average WT vehicle $2^{-\Delta CT}$. Error bars are calculated standard deviation between the biological replicates. Dashed line represent normalized WT vehicle average value of 1. Asterisk marks (*) represent calculated p-values; two-way ANOVA followed by Tukey’s multiple comparison test (p<0.05, Tukey’s). Bars marked with an asterisk mark (*) are significantly different than WT vehicle treated rats.
Figure 4. Fold Change in Transporter Gene Expression Levels in Untreated and Treated WT and Knock-out Rats. Vehicle (left cluster), PCN (middle cluster) and TCPOBOP (right cluster) treated rats Slco1a2 (A), Slco1a1 (B) and Slc10a1 (C) expression levels were normalized to WT vehicle treated rats to calculate fold changes. Fold change calculated by dividing each $2^{-\Delta CT}$ replicate reaction by the average WT vehicle $2^{-\Delta CT}$. Error bars are calculated standard deviation between replicate reactions. Dashed line represent normalized WT vehicle average value of 1. Asterisk marks (*) represent calculated p-values; two-way ANOVA followed by Tukey’s multiple comparison test (p<0.05, Tukey’s). Bars marked with an asterisk mark (*) are significantly different than WT vehicle treated rats.

Figure 5. Fold Change in Phase II Enzyme Gene Expression Levels in Untreated and Treated WT and Knock-out Rats. Vehicle (left cluster), PCN (middle cluster) and TCPOBOP (right cluster) treated rats Ugt2b1 (A), Ugt1a6 (B), Sult2a2 (C), Ephx1 (D) and Gstm4 (E) expression levels were normalized to WT vehicle treated rats to calculate fold changes. Fold change calculated by dividing each $2^{-\Delta CT}$ replicate reaction by the average WT vehicle $2^{-\Delta CT}$. Error bars are calculated standard deviation between the replicate reactions. Dashed line represent normalized WT vehicle average value of 1. A second dash line of a value of 2 added (D) to represent the range of significant change in gene expression. Asterisk marks (*) represent calculated p-values; two-way ANOVA followed by Tukey’s multiple comparison test (p<0.05, Tukey’s). Bars marked with an asterisk mark (*) are significantly different than WT vehicle treated rats.
Table 1. Fold Change of Gene Expression in PCN:Vehicle Treated Rats

<table>
<thead>
<tr>
<th>P450 Gene</th>
<th>WT</th>
<th>PXR&lt;sup&gt;-/-&lt;/sup&gt;</th>
<th>CAR&lt;sup&gt;-/-&lt;/sup&gt;</th>
<th>PXR&lt;sup&gt;-/-&lt;/sup&gt;/CAR&lt;sup&gt;-/-&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp2b2</td>
<td>2.42&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.65</td>
<td>26.76</td>
<td>1.09</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.85)</td>
<td>(+/- 0.50)</td>
<td>(+/- 23.56)</td>
<td>(+/- 0.35)</td>
</tr>
<tr>
<td>Cyp3a23/3a1</td>
<td>5.30&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.23&lt;sup&gt;**&lt;/sup&gt;</td>
<td>8.08</td>
<td>1.24&lt;sup&gt;**&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>(+/- 1.32)</td>
<td>(+/- 0.27)</td>
<td>(+/- 4.60)</td>
<td>(+/- 0.29)</td>
</tr>
<tr>
<td>Cyp3a18</td>
<td>3.78&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.19&lt;sup&gt;**&lt;/sup&gt;</td>
<td>4.86&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.19&lt;sup&gt;**&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>(+/- 1.23)</td>
<td>(+/- 0.24)</td>
<td>(+/- 2.22)</td>
<td>(+/- 0.13)</td>
</tr>
<tr>
<td>Cyp3a2</td>
<td>2.83&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.25</td>
<td>2.58&lt;sup&gt;**&lt;/sup&gt;</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>(+/- 2.23)</td>
<td>(+/- 0.36)</td>
<td>(+/- 0.70)</td>
<td>(+/- 0.35)</td>
</tr>
<tr>
<td>Cyp3a9</td>
<td>2.89&lt;sup&gt;*&lt;/sup&gt;</td>
<td>4.31&lt;sup&gt;*&lt;/sup&gt;</td>
<td>2.07</td>
<td>1.24</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.84)</td>
<td>(+/- 2.03)</td>
<td>(+/- 1.06)</td>
<td>(+/- 0.33)</td>
</tr>
<tr>
<td>Slco1a2</td>
<td>3.30&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.00&lt;sup&gt;**&lt;/sup&gt;</td>
<td>3.82&lt;sup&gt;**&lt;/sup&gt;</td>
<td>0.93&lt;sup&gt;**&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>(+/- 1.13)</td>
<td>(+/- 0.20)</td>
<td>(+/- 1.01)</td>
<td>(+/- 0.15)</td>
</tr>
<tr>
<td>Slco1a1</td>
<td>1.34</td>
<td>0.81</td>
<td>0.65</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.55)</td>
<td>(+/- 0.37)</td>
<td>(+/- 0.08)</td>
<td>(+/- 0.13)</td>
</tr>
<tr>
<td>Slc10a1</td>
<td>1.06</td>
<td>1.06</td>
<td>0.94</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.36)</td>
<td>(+/- 0.21)</td>
<td>(+/- 0.25)</td>
<td>(+/- 0.14)</td>
</tr>
<tr>
<td>Ugt2b1</td>
<td>1.87</td>
<td>0.68</td>
<td>3.65&lt;sup&gt;<strong>&lt;/sup&gt;/</strong></td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.62)</td>
<td>(+/- 0.18)</td>
<td>(+/- 0.97)</td>
<td>(+/- 0.17)</td>
</tr>
<tr>
<td>Ugt1a6</td>
<td>0.70</td>
<td>0.68</td>
<td>0.79</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.24)</td>
<td>(+/- 0.13)</td>
<td>(+/- 0.21)</td>
<td>(+/- 0.07)</td>
</tr>
<tr>
<td>Sult2a2</td>
<td>5.71&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0.67&lt;sup&gt;**&lt;/sup&gt;</td>
<td>5.04&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0.43&lt;sup&gt;**&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>(+/- 1.91)</td>
<td>(+/- 0.18)</td>
<td>(+/- 1.35)</td>
<td>(+/- 0.12)</td>
</tr>
<tr>
<td>Ephx1</td>
<td>1.24</td>
<td>0.80</td>
<td>0.84</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.42)</td>
<td>(+/- 0.16)</td>
<td>(+/- 0.22)</td>
<td>(+/- 0.07)</td>
</tr>
<tr>
<td>Gstm4</td>
<td>0.82</td>
<td>0.70</td>
<td>0.64</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.28)</td>
<td>(+/- 0.14)</td>
<td>(+/- 0.17)</td>
<td>(+/- 0.15)</td>
</tr>
</tbody>
</table>

Values are fold change PCN to vehicle treated, +/- standard deviation. 
* = significantly different from vehicle treated, same genotype (p<0.05, t-test).
Fold change between genotypes analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. ** = significantly different from WT (p<0.05, Tukey’s).
Table 2. Fold Change of Gene Expression in TCPOBOP:Vehicle Treated Rats

<table>
<thead>
<tr>
<th>P450 Gene</th>
<th>WT</th>
<th>PXR&lt;sup&gt;-/-&lt;/sup&gt;</th>
<th>CAR&lt;sup&gt;-/-&lt;/sup&gt;</th>
<th>PXR&lt;sup&gt;-/-&lt;/sup&gt;/CAR&lt;sup&gt;-/-&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp2b2</td>
<td>6.18*</td>
<td>3.65*</td>
<td>1.42**</td>
<td>0.71**</td>
</tr>
<tr>
<td></td>
<td>(+/- 2.38)</td>
<td>(+/- 0.83)</td>
<td>(+/- 1.05)</td>
<td>(+/- 0.41)</td>
</tr>
<tr>
<td>Cyp3a23/3a1</td>
<td>1.08</td>
<td>1.44</td>
<td>0.99</td>
<td>0.69</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.31)</td>
<td>(+/- 0.08)</td>
<td>(+/- 0.22)</td>
<td>(+/- 0.14)</td>
</tr>
<tr>
<td>Cyp3a18</td>
<td>1.06</td>
<td>1.21</td>
<td>1.00</td>
<td>0.76</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.29)</td>
<td>(+/- 0.17)</td>
<td>(+/- 0.23)</td>
<td>(+/- 0.15)</td>
</tr>
<tr>
<td>Cyp3a2</td>
<td>1.07</td>
<td>1.38</td>
<td>0.87</td>
<td>0.20</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.23)</td>
<td>(+/- 0.34)</td>
<td>(+/- 0.24)</td>
<td>(+/- 0.03)</td>
</tr>
<tr>
<td>Cyp3a9</td>
<td>1.68</td>
<td>5.38</td>
<td>0.70</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.84)</td>
<td>(+/- 5.35)</td>
<td>(+/- 0.27)</td>
<td>(+/- 0.20)</td>
</tr>
<tr>
<td>Slco1a2</td>
<td>1.10</td>
<td>0.88</td>
<td>0.95</td>
<td>1.26</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.17)</td>
<td>(+/- 0.24)</td>
<td>(+/- 0.31)</td>
<td>(+/- 0.28)</td>
</tr>
<tr>
<td>Slco1a1</td>
<td>0.82</td>
<td>0.79</td>
<td>0.63</td>
<td>1.19</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.14)</td>
<td>(+/- 0.37)</td>
<td>(+/- 0.11)</td>
<td>(+/- 0.24)</td>
</tr>
<tr>
<td>Slc10a1</td>
<td>0.92</td>
<td>1.25</td>
<td>1.15</td>
<td>1.26</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.14)</td>
<td>(+/- 0.35)</td>
<td>(+/- 0.37)</td>
<td>(+/- 0.28)</td>
</tr>
<tr>
<td>Ugt2b1</td>
<td>1.04</td>
<td>0.94</td>
<td>0.55</td>
<td>1.45</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.14)</td>
<td>(+/- 0.09)</td>
<td>(+/- 0.19)</td>
<td>(+/- 0.84)</td>
</tr>
<tr>
<td>Ugt1a6</td>
<td>0.78</td>
<td>1.15</td>
<td>1.26</td>
<td>1.21</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.12)</td>
<td>(+/- 0.32)</td>
<td>(+/- 0.41)</td>
<td>(+/- 0.27)</td>
</tr>
<tr>
<td>Sult2a2</td>
<td>1.20</td>
<td>0.42*</td>
<td>2.35*</td>
<td>1.16</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.16)</td>
<td>(+/- 0.04)</td>
<td>(+/- 0.80)</td>
<td>(+/- 0.67)</td>
</tr>
<tr>
<td>Ephx1</td>
<td>1.34</td>
<td>1.74</td>
<td>0.85</td>
<td>1.54</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.20)</td>
<td>(+/- 0.48)</td>
<td>(+/- 0.28)</td>
<td>(+/- 0.34)</td>
</tr>
<tr>
<td>Gstm4</td>
<td>0.65</td>
<td>0.92</td>
<td>0.59</td>
<td>1.26</td>
</tr>
<tr>
<td></td>
<td>(+/- 0.10)</td>
<td>(+/- 0.25)</td>
<td>(+/- 0.19)</td>
<td>(+/- 0.28)</td>
</tr>
</tbody>
</table>

Values are fold change TCPOBOP to vehicle treated, +/- standard deviation. * = significantly different from vehicle treated, same genotype (p<0.05, t-test). Fold change between genotypes analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. ** = significantly different from WT (p<0.05, Tukey's)
**Figure 1.**

**A**
Wild type PXR allele: 5' - CAAAAAGGCGCGCAACGTACGCGGATG-3'
Knockout allele: 5' - CAAAAAGGCGCGCAACGTACGCGGATG-3'

**B**
Wild type CAR allele: 5' - GACGTGTGTCGTTGAGAGAAGACAAGCTGCTGAGG-3'
Knockout allele: 5' - GACGTGTGTCGTTGAGAGAAGACAAGCTGCTGAGG-3'

**C**

WT  |  PXR-
---  |  ---
50 kD | 50 kD
Figure 2.
Figure 3.

A

Cyp2b2

Fold change over WT vehicle

WT
PXR
CAR
PXR+CAR

B

Cyp3a23/Sa1

Fold change over WT vehicle

WT
PXR
CAR
PXR+CAR

C

Cyp3a18

Fold change over WT vehicle

WT
PXR
CAR
PXR+CAR

D

Cyp3a2

Fold change over WT vehicle

WT
PXR
CAR
PXR+CAR

E

Cyp3a11

Fold change over WT vehicle

WT
PXR
CAR
PXR+CAR

Legend:

- **Vehicle**
- **PCN**
- **TCPOBOP**
Figure 4.

A

$\text{Slco1a2}$

Fold change over WT vehicle

B

$\text{Slco1a1}$

Fold change over WT vehicle

C

$\text{5lc10a1}$

Fold change over WT vehicle
Figure 5.